Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local
This article was originally published in The Pink Sheet Daily
Executive Summary
Russia has said clearly that it wants Big Pharma to localize production and help transfer technology and know-how to domestic companies, raising the question of how Pharma can both go local and be profitable.
You may also be interested in...
Priming Russia’s Pharma Industry For Innovation
The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 Million
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets.